Last reviewed · How we verify
LY2780301
At a glance
| Generic name | LY2780301 |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer (PHASE1, PHASE2)
- A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine (PHASE1)
- A Study in Patients With Advanced or Metastatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY2780301 CI brief — competitive landscape report
- LY2780301 updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI